Portfolio October 8, 2026 Endeavor BioMedicines’ WHISTLE-PF Phase 2b Trial of Taladegib Meets Primary and Key Secondary Endpoints in Patients with IPF Read more
Portfolio October 5, 2026 iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care Read more
Portfolio July 15, 2026 AdvanCell Closes $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial... Read more
Portfolio April 14, 2026 Calyxo Secures $40 Million Series F Financing as CVAC System Surpasses 40,000 Patients Treated for Kidney Stone Removal Read more
Portfolio February 2, 2026 Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Read more
